The ADVOR trial found that acetazolamide can increase the rate of successful decongestion in patients with acute decompensated heart failure, regardless of their renal function. This means that acetazolamide can be an effective treatment option for patients experiencing heart failure exacerbations. The study suggests that the drug can help improve outcomes for these patients. By continuing to use our site, you agree to our use of cookies for analytics, advertising, and site improvement. To learn more about our cookie usage, please refer to our Cookie Policy and Cookie Settings.
Source link
Acetazolamide ups rate of successful decongestion in acute decompensated heart failure, regardless of renal function: ADVOR trial
